Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Liquid biopsy sits at the center of this dementia and brain health question.
Liquid biopsy approaches for Alzheimer’s disease detection have moved from research laboratories into routine clinical practice. Over the past two years, the Food and Drug Administration has cleared multiple blood tests that can identify Alzheimer’s-related brain changes—specifically amyloid plaques and phosphorylated tau accumulation—through a simple blood draw rather than expensive imaging or invasive procedures. This represents a fundamental shift in how doctors can approach early diagnosis and brain monitoring in patients with cognitive symptoms. The breakthrough came with FDA approval of blood-based biomarker tests starting in May 2025, when the Lumipulse G test using the plasma pTau217/Aβ1-42 ratio received clearance for diagnosing amyloid plaques in symptomatic patients age 55 and older.
By October 2025, Roche’s Elecsys pTau181 became available as an FDA-cleared test specifically designed for use in primary care settings to rule out Alzheimer’s-related amyloid pathology. These tests measure specific proteins in the blood that reflect what is happening inside the brain—without requiring a patient to undergo PET imaging, MRI scans, or lumbar puncture. What makes this development significant is the accessibility it offers. People at risk for cognitive decline can now receive answers in their doctor’s office using standard laboratory equipment, rather than traveling to specialized imaging centers or undergoing procedures typically reserved for research studies. The tests have been validated across thousands of participants and are already being offered through major laboratory networks like Labcorp.
Table of Contents
- How Do Blood-Based Biomarker Tests Detect Alzheimer’s Changes?
- FDA Approvals, Clinical Evidence, and What Tests Are Available Now
- Which Proteins Are Being Measured and Why They Matter
- How Liquid Biopsy Compares to Traditional Diagnostic Approaches
- Important Limitations and Considerations for Patients and Providers
- Real-World Availability and How to Access Testing
- What Comes Next—Future Directions in Liquid Biopsy and Brain Monitoring
- Conclusion
How Do Blood-Based Biomarker Tests Detect Alzheimer’s Changes?
Liquid biopsy in the context of Alzheimer’s disease works by measuring proteins in the blood that correlate with pathological changes occurring in the brain. The primary targets are phosphorylated tau (pTau)—specifically variants like pTau217 and pTau181—and amyloid-beta (Aβ1-42), the two hallmark proteins that accumulate abnormally in Alzheimer’s brains. When these proteins misfold and aggregate in neural tissue, fragments and modified versions leak into the bloodstream, where they can be detected through sensitive laboratory assays. The clinical validation has been substantial. In a multi-cohort study involving 7,252 participants, the Elecsys pTau217 plasma immunoassay achieved an area under curve (AUC) of 0.878 or higher when compared against amyloid PET imaging across cognitively diverse populations.
This means the blood test was highly accurate at distinguishing between people with and without amyloid pathology in their brains. The test performed consistently across different age groups and cognitive statuses, making it reliable for clinical decision-making. The advantage over PET imaging is substantial. A PET scan requires specialized equipment, often months of waiting, and significant cost. A blood test uses standard laboratory equipment, produces results within days, and can be performed during a routine office visit. For example, a 62-year-old patient with mild memory problems can have blood drawn during their annual physical, and the results can help determine whether their symptoms are related to Alzheimer’s pathology or another cause.
FDA Approvals, Clinical Evidence, and What Tests Are Available Now
The regulatory pathway accelerated considerably in 2024 and 2025. In April 2024, Roche’s Elecsys pTau217 assay received FDA Breakthrough Device Designation in collaboration with Eli Lilly, signaling that regulators recognized its potential to improve patient care for Alzheimer’s diagnosis. This designation fast-tracked the approval process. The actual FDA clearances followed: Lumipulse G in May 2025 and Roche’s Elecsys pTau181 in October 2025. The distinction between these tests matters for clinical practice. The pTau181 test is specifically cleared for use in primary care to rule out Alzheimer’s-related amyloid pathology—meaning a negative result in a symptomatic patient can help eliminate Alzheimer’s as a diagnosis. The pTau217 test, validated across the largest and most diverse patient populations, offers diagnostic confirmation.
Both tests are intended for individuals aged 55 to 60 years and older who are experiencing cognitive symptoms. They are not screening tools for asymptomatic people, and they should be interpreted alongside clinical evaluation and cognitive testing. A limitation worth noting: these tests measure biomarkers, not symptoms. A positive result means amyloid pathology is present, but it does not tell the doctor how quickly symptoms will progress, whether the person will develop dementia, or which treatment might work best. Biomarker positivity can precede symptoms by years. Some cognitively normal older adults have positive biomarkers and never develop dementia during their lifetime. This gap between what the blood test shows and what it predicts about an individual patient’s future remains an active area of research.
Which Proteins Are Being Measured and Why They Matter
The phosphorylated tau variants (pTau217 and pTau181) are central to current blood tests because they appear to be highly specific for Alzheimer’s pathology. Tau proteins are normally present in neurons and help stabilize the cellular skeleton. In Alzheimer’s disease, tau becomes hyperphosphorylated—meaning chemical phosphate groups accumulate on the protein—causing it to misfold and form tangles inside neurons. These phosphorylated forms in the blood reflect tau pathology in the brain. Amyloid-beta 1-42 (Aβ1-42) is the other key marker. Amyloid-beta is a fragment produced when a larger protein is broken down, and it tends to aggregate and form plaques between neurons.
In Alzheimer’s disease, levels of Aβ1-42 in the cerebrospinal fluid decrease (because it is being deposited as plaques in the brain), and correspondingly, the Aβ1-42 to phosphorylated tau ratio can indicate amyloid pathology. The Lumipulse G test uses the ratio of pTau217 to Aβ1-42 to make its determination. Some researchers and clinicians are interested in additional biomarkers, such as phosphorylated tau at other sites (pTau385, pTau399) and neurofilament light chain, which reflects neuronal damage. However, the tests currently available and approved focus on the established tau and amyloid markers. This means that other important aspects of brain pathology—neuroinflammation, vascular damage, or non-Alzheimer’s causes of dementia—are not directly measured by these blood tests. A patient with a negative amyloid and tau biomarker panel could still have cognitive decline from vascular disease, Lewy body pathology, or other causes.
How Liquid Biopsy Compares to Traditional Diagnostic Approaches
The traditional pathway for confirming Alzheimer’s pathology has relied on PET imaging (either amyloid PET or tau PET) or cerebrospinal fluid analysis via lumbar puncture. Both approaches have drawbacks. PET imaging is expensive—often $3,000 to $5,000 per scan—requires specialized equipment available only at major medical centers, and involves radiation exposure. Lumbar puncture is invasive, carries a small risk of complications, and many patients are understandably reluctant to undergo it. Liquid biopsy offers a middle ground: it is non-invasive, uses standard laboratory infrastructure, costs a fraction of PET imaging, and can be accessed in primary care settings. Labcorp, one of the largest laboratory networks in the United States, is already offering FDA-cleared blood tests for Alzheimer’s-related amyloid pathology detection.
This means millions of Americans have access to testing through their routine healthcare provider. A comparison: a patient with cognitive concerns might have waited six months for a PET scan appointment; now they can have blood drawn at a routine visit and receive results within a week. However, liquid biopsy does have a trade-off. It is less precise than PET imaging in some respects. PET shows the spatial distribution of pathology—where in the brain plaques and tangles are accumulating—which can guide discussions about prognosis and cognitive domains at risk. A blood test provides a summary measure of overall pathology burden. Additionally, blood tests are optimized for detecting amyloid pathology but are less well-established for tracking subtle changes over time or predicting which cognitive domains will be affected first in an individual patient.
Important Limitations and Considerations for Patients and Providers
The blood tests are not diagnostic of dementia—they are diagnostic of Alzheimer’s pathology. This distinction is crucial. A person can have amyloid and tau in their brain yet remain cognitively normal, particularly if they are younger or have protective genetic factors. Conversely, a cognitively impaired patient with a negative biomarker test may still have Alzheimer’s-related dementia if they have primarily tau pathology without amyloid (a scenario called primary age-related tauopathy or PART), or they may have a non-Alzheimer’s dementia altogether. The age restriction is also important. The FDA-cleared tests are intended for individuals aged 55 years and older with cognitive symptoms.
They have not been validated in younger patients. Testing asymptomatic adults without cognitive concerns is not recommended based on current evidence and guidelines. The presence of biomarkers in a cognitively normal person raises difficult counseling questions: should they start disease-modifying medications? What lifestyle changes are indicated? How will they be monitored? These questions are still being worked out in clinical practice. One significant warning: the availability of these tests has outpaced the evidence about what to do with the results. The most effective treatments currently available—monoclonal antibodies like aducanumab, lecanemab, and donanemab—slow cognitive decline in early symptomatic stages but do not cure or reverse Alzheimer’s. They carry risks, including amyloid-related imaging abnormalities (ARIA), which can cause brain microhemorrhages or microinfarcts. A positive blood biomarker test should lead to further cognitive assessment and informed shared decision-making about treatment, not automatic medication.
Real-World Availability and How to Access Testing
As of early 2026, blood tests for Alzheimer’s biomarkers are available through major clinical laboratory networks. Roche’s tests (pTau217 and pTau181) are available internationally, with CE Mark approval for European markets as of July 2025. In the United States, Labcorp and other major laboratories offer FDA-cleared tests. A patient or family member concerned about cognitive changes should discuss testing with their primary care physician or a neurologist. The doctor will typically conduct cognitive screening (such as the Montreal Cognitive Assessment or Mini-Cog) first, to determine whether biomarker testing is appropriate, since the tests are most useful in people with documented cognitive symptoms. The testing process is straightforward. A blood sample is collected at a local laboratory or phlebotomy center, processed, and sent to a central facility where the specialized immunoassays are performed. Results typically return within one to two weeks.
Insurance coverage varies but is improving as these tests become FDA-cleared and more widely accepted. Some health systems and insurance companies now cover the tests for symptomatic patients, especially if a specialist has recommended testing. What testing does not provide is certainty about the future. A positive result suggests increased risk and the presence of pathology, but it does not predict whether dementia will develop or how quickly. This uncertainty is difficult for patients and families who want definitive answers. Some patients find the information empowering—it allows them to plan, consider treatment options, and make lifestyle decisions. Others find it anxiety-provoking without clear next steps. This is why follow-up consultation with a cognitive specialist, neurologist, or geriatrician is strongly recommended after an abnormal result.
What Comes Next—Future Directions in Liquid Biopsy and Brain Monitoring
The field is moving rapidly toward more sensitive and earlier detection. Researchers are investigating whether blood biomarkers can identify Alzheimer’s pathology in cognitively normal people and predict who will develop symptoms within a specific timeframe. Longitudinal studies are underway to determine the prognostic value of serial measurements—whether watching biomarker levels change over time can better predict cognitive decline than a single measurement.
Additional biomarkers are also in development, including phosphorylated tau at other sites, neurofilament light chain (which indicates neuronal injury), and inflammation markers. These could eventually allow a more comprehensive blood-based assessment that captures multiple pathological processes occurring in the brain. Liquid biopsy may eventually play a role not only in diagnosis but in monitoring treatment response and detecting early signs of cognitive change in people at risk. The vision is a future where brain health monitoring is as routine as checking cholesterol levels, performed at regular intervals to catch changes early.
Conclusion
Liquid biopsy approaches for Alzheimer’s disease represent a major advance in accessibility and early detection. The FDA approvals of blood tests measuring phosphorylated tau and amyloid-beta over 2024 and 2025 have moved diagnosis out of specialized imaging centers and into primary care offices. These tests are non-invasive, accurate, and available through major laboratory networks, making them accessible to millions of people with cognitive concerns. For many patients and families, this means answers that were previously impossible to obtain without invasive procedures or expensive imaging are now within reach.
However, a positive blood test result is a beginning, not an ending. It indicates the presence of Alzheimer’s pathology but requires follow-up cognitive assessment, discussion of treatment options, and planning for long-term care and monitoring. Patients should discuss results with their healthcare provider, seek specialist consultation if appropriate, and engage in lifestyle measures known to support brain health. As research continues and more data accumulate on how to manage people identified through biomarker testing, the role of liquid biopsy in dementia care will continue to evolve.
You Might Also Like
- Brain Cell Support Systems Emerge as Alzheimer’s Treatment Targets
- Technology Startups Focus on Alzheimer’s Detection and Management
- Sensor Technology Enables Continuous Alzheimer’s Symptom Assessment
For more, see Alzheimer’s Association — medical tests.
